836 related articles for article (PubMed ID: 15954895)
1. Stimulation of soluble guanylate cyclase slows progression in anti-thy1-induced chronic glomerulosclerosis.
Wang Y; Krämer S; Loof T; Martini S; Kron S; Kawachi H; Shimizu F; Neumayer HH; Peters H
Kidney Int; 2005 Jul; 68(1):47-61. PubMed ID: 15954895
[TBL] [Abstract][Full Text] [Related]
2. Expression and activity of soluble guanylate cyclase in injury and repair of anti-thy1 glomerulonephritis.
Peters H; Wang Y; Loof T; Martini S; Kron S; Krämer S; Neumayer HH
Kidney Int; 2004 Dec; 66(6):2224-36. PubMed ID: 15569311
[TBL] [Abstract][Full Text] [Related]
3. Enhancing cGMP in experimental progressive renal fibrosis: soluble guanylate cyclase stimulation vs. phosphodiesterase inhibition.
Wang Y; Krämer S; Loof T; Martini S; Kron S; Kawachi H; Shimizu F; Neumayer HH; Peters H
Am J Physiol Renal Physiol; 2006 Jan; 290(1):F167-76. PubMed ID: 16048904
[TBL] [Abstract][Full Text] [Related]
4. Selective lymphocyte inhibition by FTY720 slows the progressive course of chronic anti-thy 1 glomerulosclerosis.
Peters H; Martini S; Wang Y; Shimizu F; Kawachi H; Krämer S; Neumayer HH
Kidney Int; 2004 Oct; 66(4):1434-43. PubMed ID: 15458436
[TBL] [Abstract][Full Text] [Related]
5. Mycophenolate mofetil slows progression in anti-thy1-induced chronic renal fibrosis but is not additive to a high dose of enalapril.
Krämer S; Loof T; Martini S; Rückert M; Wang Y; Böhler T; Shimizu F; Kawachi H; Neumayer HH; Peters H
Am J Physiol Renal Physiol; 2005 Aug; 289(2):F359-68. PubMed ID: 15769934
[TBL] [Abstract][Full Text] [Related]
6. Stimulation of soluble guanylate cyclase improves renal recovery after relief of unilateral ureteral obstruction.
Wang-Rosenke Y; Mika A; Khadzhynov D; Loof T; Neumayer HH; Peters H
J Urol; 2011 Sep; 186(3):1142-9. PubMed ID: 21784461
[TBL] [Abstract][Full Text] [Related]
7. NO mediates antifibrotic actions of L-arginine supplementation following induction of anti-thy1 glomerulonephritis.
Peters H; Daig U; Martini S; Rückert M; Schäper F; Liefeldt L; Krämer S; Neumayer HH
Kidney Int; 2003 Aug; 64(2):509-18. PubMed ID: 12846746
[TBL] [Abstract][Full Text] [Related]
8. Low-dose mTOR inhibition by rapamycin attenuates progression in anti-thy1-induced chronic glomerulosclerosis of the rat.
Krämer S; Wang-Rosenke Y; Scholl V; Binder E; Loof T; Khadzhynov D; Kawachi H; Shimizu F; Diekmann F; Budde K; Neumayer HH; Peters H
Am J Physiol Renal Physiol; 2008 Feb; 294(2):F440-9. PubMed ID: 18094032
[TBL] [Abstract][Full Text] [Related]
9. Impact of biological gender and soluble guanylate cyclase stimulation on renal recovery after relief of unilateral ureteral obstruction.
Wang-Rosenke Y; Mika A; Khadzhynov D; Loof T; Neumayer HH; Peters H
J Urol; 2012 Jul; 188(1):316-23. PubMed ID: 22608751
[TBL] [Abstract][Full Text] [Related]
10. Stimulation of soluble guanylyl cyclase inhibits mesangial cell proliferation and matrix accumulation in experimental glomerulonephritis.
Hohenstein B; Daniel C; Wagner A; Stasch JP; Hugo C
Am J Physiol Renal Physiol; 2005 Apr; 288(4):F685-93. PubMed ID: 15561976
[TBL] [Abstract][Full Text] [Related]
11. Vas deferens smooth muscle responses to the nitric oxide-independent soluble guanylate cyclase stimulator BAY 41-2272.
da Silva FH; Claudino MA; Báu FR; Rojas-Moscoso JA; Mónica FZ; De Nucci G; Antunes E
Eur J Pharmacol; 2012 Aug; 688(1-3):49-55. PubMed ID: 22634166
[TBL] [Abstract][Full Text] [Related]
12. Activators and stimulators of soluble guanylate cyclase counteract myofibroblast differentiation of prostatic and dermal stromal cells.
Zenzmaier C; Kern J; Heitz M; Plas E; Zwerschke W; Mattesich M; Sandner P; Berger P
Exp Cell Res; 2015 Nov; 338(2):162-9. PubMed ID: 26410556
[TBL] [Abstract][Full Text] [Related]
13. S1P modulator FTY720 limits matrix expansion in acute anti-thy1 mesangioproliferative glomerulonephritis.
Martini S; Krämer S; Loof T; Wang-Rosenke Y; Daig U; Budde K; Neumayer HH; Peters H
Am J Physiol Renal Physiol; 2007 Jun; 292(6):F1761-70. PubMed ID: 17356129
[TBL] [Abstract][Full Text] [Related]
14. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease.
Boerrigter G; Burnett JC
Cardiovasc Drug Rev; 2007; 25(1):30-45. PubMed ID: 17445086
[TBL] [Abstract][Full Text] [Related]
15. Nitric oxide-independent activation of soluble guanylate cyclase by BAY 60-2770 in experimental liver fibrosis.
Knorr A; Hirth-Dietrich C; Alonso-Alija C; Härter M; Hahn M; Keim Y; Wunder F; Stasch JP
Arzneimittelforschung; 2008; 58(2):71-80. PubMed ID: 18412020
[TBL] [Abstract][Full Text] [Related]
16. Increased cyclic guanosine monophosphate synthesis and calcium entry blockade account for the relaxant activity of the nitric oxide-independent soluble guanylyl cyclase stimulator BAY 41-2272 in the rabbit penile urethra.
Toque HA; Antunes E; Teixeira CE; De Nucci G
Urology; 2008 Sep; 72(3):711-5. PubMed ID: 18359064
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the relaxant effect of the nitric oxide-independent soluble guanylyl cyclase stimulator BAY 41-2272 in isolated detrusor smooth muscle.
Báu FR; Mónica FZ; Priviero FB; Baldissera L; de Nucci G; Antunes E
Eur J Pharmacol; 2010 Jul; 637(1-3):171-7. PubMed ID: 20399768
[TBL] [Abstract][Full Text] [Related]
18. Rosuvastatin is additive to high-dose candesartan in slowing progression of experimental mesangioproliferative glomerulosclerosis.
Krämer S; Kron S; Wang-Rosenke Y; Loof T; Khadzhynov D; Morgera S; Kawachi H; Shimizu F; Martini S; Neumayer HH; Peters H
Am J Physiol Renal Physiol; 2008 Apr; 294(4):F801-11. PubMed ID: 18216152
[TBL] [Abstract][Full Text] [Related]
19. The Novel, Clinical-Stage Soluble Guanylate Cyclase Activator BI 685509 Protects from Disease Progression in Models of Renal Injury and Disease.
Reinhart GA; Harrison PC; Lincoln K; Chen H; Sun P; Hill J; Qian HS; McHugh MC; Clifford H; Ng KJ; Wang H; Fowler D; Gueneva-Boucheva K; Brenneman JB; Bosanac T; Wong D; Fryer RM; Sarko C; Boustany-Kari CM; Pullen SS
J Pharmacol Exp Ther; 2023 Mar; 384(3):382-392. PubMed ID: 36507845
[TBL] [Abstract][Full Text] [Related]
20. Effects of BAY 41-2272, an activator of nitric oxide-independent site of soluble guanylate cyclase, on human NADPH oxidase system from THP-1 cells.
Borges de Oliveira-Junior E; Thomazzi SM; Rehder J; Antunes E; Condino-Neto A
Eur J Pharmacol; 2007 Jul; 567(1-2):43-9. PubMed ID: 17499238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
